This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (19) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chick, J. Articles by Landron, F. Search for Related Content PubMed PubMed Citation Articles by Chick, J. Articles by Landron, F. Social Bookmarking                         What's this?

Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence?

Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital Edinburgh UKjchick{at}compuserve.com

Philippe Lehert

Department of Statistics University of Mons Mons Belgium

Frederic Landron

Merck-Santé, Lyon France

The study aimed to discover whether acamprosate reduces the severity of relapse for those patients undergoing abstinence–orientated treatment who are unable to abstain completely. Data on patients’ alcohol consumption from 15 placebo-controlled treatment studies (n = 3309) were examined to test whether, at a given time point, patients who have taken one or more drinks since the last assessment (‘relapsers’, n = 1010) take alcohol on fewer days, report lower average number of drinks per day, and consume less alcohol in total with acamprosate compared to placebo. These studies had varying duration (90 days, 180 days and 360 days). There were four dates that were common to some studies (days 30, 90, 180 and 360). Among relapsers, acamprosate was significantly associated with less quantity (Q) and frequency (F) of drinking compared to placebo in each of the four follow-up periods (p < 0.001). The differences were most marked for the product Q x F (overall weekly consumption). For each period, there were fewer who were drinking an average of five or more drinks per day in the acamprosate compared to the placebo groups. Acamprosate helps reduce the severity of relapse in patients undergoing abstinence-orientated treatment.

Key Words: acamprosate • alcohol consumption • binge drinking • controlled drinking • lapse • outcome • relapse • treatment

Journal of Psychopharmacology, Vol. 17, No. 4, 397-402 (2003)
DOI: 10.1177/0269881103174017


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Mutschler, M. Grosshans, A. Koopmann, D. Hermann, A. Diehl, K. Mann, and F. Kiefer Supervised Disulfiram in Relapse Prevention in Alcohol-Dependent Patients Suffering From Comorbid Borderline Personality Disorder--A Case Series Alcohol Alcohol., March 1, 2010; 45(2): 146 - 150. [Abstract] [Full Text] [PDF]

				S. Carnicella, V. Kharazia, J. Jeanblanc, P. H. Janak, and D. Ron GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse PNAS, June 10, 2008; 105(23): 8114 - 8119. [Abstract] [Full Text] [PDF]

				S. Rosner, S. Leucht, P. Lehert, and M. Soyka Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes J Psychopharmacol, January 1, 2008; 22(1): 11 - 23. [Abstract] [PDF]

				J. M. Jonas and S. Chabac Pharmacotherapy and behavioral intervention for alcohol dependence. JAMA, October 11, 2006; 296(14): 1727 - 1727. [Full Text] [PDF]

				B. J. Mason Acamprosate for Alcohol Dependence: An Update for the Clinician Focus, September 1, 2006; 4(4): 505. [Abstract] [Full Text] [PDF]

				A. DE SOUSA and A. DE SOUSA AN OPEN RANDOMIZED STUDY COMPARING DISULFIRAM AND ACAMPROSATE IN THE TREATMENT OF ALCOHOL DEPENDENCE Alcohol Alcohol., November 1, 2005; 40(6): 545 - 548. [Abstract] [Full Text] [PDF]

				F. POLDRUGO, D.-A. HAEGER, S. COMTE, J. WALBURG, and A. J. PALMER A CRITICAL REVIEW OF PHARMACOECONOMIC STUDIES OF ACAMPROSATE Alcohol Alcohol., September 1, 2005; 40(5): 422 - 430. [Abstract] [Full Text] [PDF]

				A. R. Lingford-Hughes, S. Welch, and D. J. Nutt Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, September 1, 2004; 18(3): 293 - 335. [PDF]

				A. Hammarberg, P. Wennberg, O. Beck, and J. Franck A COMPARISON OF TWO INTENSITIES OF PSYCHOSOCIAL INTERVENTION FOR ALCOHOL DEPENDENT PATIENTS TREATED WITH ACAMPROSATE Alcohol Alcohol., May 1, 2004; 39(3): 251 - 255. [Abstract] [Full Text] [PDF]